177Lu-PSMA-617
Checked 2026-09-09
PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane
One cycle
every 42 days × 6 · about 36 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Lutetium-177 vipivotide tetraxetan Radioligand therapy (beta) | 7.4 GBq | IV | D1 |
Cycles
6
42-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- Dry mouth, nausea, fatigue and cytopenias; renal function and marrow reserve are checked before each cycle.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Docetaxel + prednisone
Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer
every 21 days × 6
Cabazitaxel + prednisone
Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor
every 21 days
Abiraterone + prednisone with ADT
High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer
every 28 days
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2